Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Vebeglogene autotemcel by Lantu Biopharma for Beta Thalassaemia: Likelihood of Approval
Vebeglogene autotemcel is under clinical development by Lantu Biopharma and currently in Phase II for Beta Thalassaemia. According to GlobalData,...